BACKGROUND: In preclinical hemophilia research, an animal model that reflects both the phenotype and the pathology of the disease is needed. OBJECTIVES: Here, we describe the generation and characterization of a novel genetically engineered F8(-/-) rat model. METHODS: The rats were produced on a Sprague Dawley background with the zinc finger nuclease technique. A founder with a 13-bp deletion in exon 16 causing a premature translational stop in the C-terminal part of the A3 domain of factor VIII was selected, and a breeding colony was established. RESULTS: Seventy per cent of the homozygous rats had clinically manifest spontaneous hemorrhagic episodes that needed treatment. The F8(-/-) rats had no detectable FVIII activity, and had a significantly prolonged activated partial thromboplastin time (APTT) and clot formation time as compared with wild-type (WT)/WT rats. In vitro spiking of rat plasma with human recombinant FVIII resulted in dose-dependent normalization of the APTT. CONCLUSION: On the basis of the targeted deletion in F8, and the distinct physical and analytic characteristics of the rat, we conclude that an FVIII-deficient rat strain has been generated that has the potential to contribute greatly to translational research.
BACKGROUND: In preclinical hemophilia research, an animal model that reflects both the phenotype and the pathology of the disease is needed. OBJECTIVES: Here, we describe the generation and characterization of a novel genetically engineered F8(-/-) rat model. METHODS: The rats were produced on a Sprague Dawley background with the zinc finger nuclease technique. A founder with a 13-bp deletion in exon 16 causing a premature translational stop in the C-terminal part of the A3 domain of factor VIII was selected, and a breeding colony was established. RESULTS: Seventy per cent of the homozygous rats had clinically manifest spontaneous hemorrhagic episodes that needed treatment. The F8(-/-) rats had no detectable FVIII activity, and had a significantly prolonged activated partial thromboplastin time (APTT) and clot formation time as compared with wild-type (WT)/WT rats. In vitro spiking of rat plasma with human recombinant FVIII resulted in dose-dependent normalization of the APTT. CONCLUSION: On the basis of the targeted deletion in F8, and the distinct physical and analytic characteristics of the rat, we conclude that an FVIII-deficient rat strain has been generated that has the potential to contribute greatly to translational research.
Authors: Jay N Lozier; Mark T Kloos; Elizabeth P Merricks; Nathaly Lemoine; Margaret H Whitford; Robin A Raymer; Dwight A Bellinger; Timothy C Nichols Journal: Comp Med Date: 2016 Impact factor: 0.982
Authors: R Stagaard; M J Flick; B Bojko; K Goryński; P Z Goryńska; C D Ley; L H Olsen; T Knudsen Journal: J Thromb Haemost Date: 2018-06-21 Impact factor: 5.824
Authors: Shannon M Zintner; Juliana C Small; Giulia Pavani; Lynn Dankner; Oscar A Marcos-Contreras; Phyllis A Gimotty; Mads Kjelgaard-Hansen; Bo Wiinberg; Paris Margaritis Journal: Blood Adv Date: 2019-02-12
Authors: Karin M Lövgren; Malte S Larsen; Shannon M Zintner; Juliana C Small; Mads Kjelgaard-Hansen; Mattias Häger; Maj Petersen; Bo Wiinberg; Paris Margaritis Journal: J Thromb Haemost Date: 2020-04-16 Impact factor: 5.824
Authors: B N Chao; W H Baldwin; J F Healey; E T Parker; K Shafer-Weaver; C Cox; P Jiang; C Kanellopoulou; P Lollar; S L Meeks; M J Lenardo Journal: J Thromb Haemost Date: 2016-01-08 Impact factor: 5.824
Authors: Jessica Garcia; Veronica H Flood; Sandra L Haberichter; Scot A Fahs; Jeremy G Mattson; Aron M Geurts; Mark Zogg; Hartmut Weiler; Qizhen Shi; Robert R Montgomery Journal: Res Pract Thromb Haemost Date: 2019-12-29
Authors: Astrid E Pulles; Kåre K Vøls; Kristine R Christensen; Katja Coeleveld; Axel K Hansen; Lize F D van Vulpen; Maj Petersen; Simon C Mastbergen; Kirstine Roepstorff; Roger E G Schutgens; Mads Kjelgaard-Hansen; Floris P J G Lafeber Journal: Haemophilia Date: 2020-03-25 Impact factor: 4.287